Despite demonstrated benefits in adherence support and relapse prevention, long-acting injectable (LAI) antipsychotics remain underutilized relative to their clinical potential in community psychiatric settings. Understanding the multilayered barriers to broader adoption is essential for clinicians seeking to integrate these options more consistently into routine practice.1-3
Patient-level barriers frequently include misconceptions about injection-based treatment, concerns about pain or injection site reactions, and stigma associated with what some perceive as a more restrictive form of medication delivery. Clinicians also report perceived dislike of needles, cost, and patient refusal of LAI secondary to stigma surrounding the diagnosis of schizophrenia as potential barriers.3,4 Reframing LAIs as an advanced delivery system that simplifies treatment and supports independence, rather than representing escalated intervention, can shift these perceptions meaningfully. Involving family members and caregivers in early conversations reinforces this framing and builds a broader support network around treatment engagement.3,4 For patients with concerns about intramuscular administration, subcutaneous formulations may offer a more acceptable alternative. Subcutaneous delivery typically involves smaller needles and more flexible injection sites such as the abdomen or back of the upper arm, and may be associated with less injection discomfort.1,5
At the practice level, unfamiliarity with newer LAI formulations, uncertainty about insurance authorization pathways, and limited relationships with specialty pharmacies contribute to implementation friction.3 Proactive engagement with pharmacy partners, familiarity with prior authorization requirements for available agents, and in-office workflows that support injection administration are practical investments that reduce barriers to initiation and continuity.4 Clinician familiarity with the full range of available formulations, including newer agents not requiring a loading dose or oral supplementation at initiation, can simplify treatment starts and expand the options available to patients who have struggled with initiation complexity in the past.1
Clinicians play a central role in delivering guideline-concordant schizophrenia care across mental health clinics, primary care, and community settings. Evidence suggests that patients managed by psychiatric advanced practice providers receive similar rates of evidence-based care as those managed by psychiatrists, underscoring the opportunity for this prescriber group to expand LAI access.6 As newer formulations enter the market with simplified initiation protocols and alternative delivery routes, ongoing education tailored to care team members becomes increasingly important in ensuring these options reach the patients most likely to benefit.1
Cross-specialty education, institutional support, and access to psychosocial services remain areas where targeted investment can improve both care quality and treatment outcomes across diverse practice environments.
Take our schizophrenia quiz to see how your knowledge compares to your peers.
